Welcome to our dedicated page for ORGANON & CO news (Ticker: OGN), a resource for investors and traders seeking the latest updates and insights on ORGANON & CO stock.
Organon & Co (OGN) delivers science-driven healthcare solutions through its focus on women’s health, biosimilars, and established medicines. This page provides investors and industry professionals with a centralized hub for tracking the company’s latest developments and strategic initiatives.
Access real-time updates including earnings reports, regulatory milestones, product launches, and partnership announcements. Our curated collection ensures you stay informed about OGN’s progress in addressing global healthcare needs while maintaining compliance with evolving industry standards.
Key updates cover clinical trial results, market expansion efforts, and leadership changes impacting OGN’s operations across Europe, North America, and Asia-Pacific regions. All content is verified for accuracy to support informed analysis of the company’s pharmaceutical innovations and business strategy.
Bookmark this page for streamlined access to Organon &’s official communications and third-party analyses. Regularly updated content helps stakeholders monitor the company’s position in competitive therapeutic markets and evolving healthcare landscapes.
Organon (NYSE: OGN), a global healthcare company focused on women's health, has announced the appointment of Ramona A. Sequeira to its Board of Directors, effective July 1, 2025. Sequeira, currently President of the Global Portfolio Division at Takeda Pharmaceutical Company, will serve on the Board's Talent Committee.
The appointment expands Organon's Board to 12 directors. Sequeira brings over 30 years of pharmaceutical industry experience, including 20 years at Eli Lilly and 10 years at Takeda. At Takeda, she leads business units across Europe, Canada, China, and Growth and Emerging Markets, while overseeing the Vaccines Business Unit and Global Medical and Commercial Strategy functions.
Sequeira's notable achievements include being the first woman to Chair the Pharmaceutical Research and Manufacturers of America Board of Directors. She currently serves on the Board of Directors of Edwards Life Sciences.
Organon (NYSE: OGN), a global healthcare company focused on women's health, has scheduled its first quarter 2025 financial results release for May 1, 2025. The company will host a webcast and conference call at 8:30 a.m. EDT on the same day.
The company anticipates recording approximately $6 million in milestone expenses for Q1 2025. However, Organon notes that IPR&D (in-process research and development) and milestone expenses are not included in their financial guidance from February 13, 2025, due to uncertainty in timing and forecasting such achievements.
The Q1 2025 results remain subject to quarterly financial statement closing procedures, and actual results may differ from preliminary estimates.
Organon (NYSE: OGN) has acquired U.S. regulatory and commercial rights for TOFIDENCE™, a biosimilar to ACTEMRA®, from Biogen Inc. (Nasdaq: BIIB). TOFIDENCE, launched in May 2024, is the first approved tocilizumab biosimilar in the U.S. market for intravenous infusion.
The treatment is indicated for multiple conditions including rheumatoid arthritis, giant cell arteritis, polyarticular juvenile idiopathic arthritis, systemic juvenile idiopathic arthritis, and COVID-19. The acquisition includes three vial sizes: 80 mg/4 mL, 200 mg/10 mL, and 400 mg/20 mL.
The deal structure includes an upfront payment to Biogen, with Organon assuming tiered royalty payments based on net sales and annual net sales milestone payments owed to Bio-Thera Solutions , who will maintain manufacturing rights for the U.S. market.
Henlius Biotech (2696.HK) and Organon (NYSE: OGN) announced that the European Medicines Agency (EMA) has validated their marketing authorization application for HLX11, a biosimilar candidate of Perjeta® (pertuzumab).
The application is supported by a multicenter, randomized, double-blind phase 3 clinical study that compared HLX11 with Perjeta® in HER2-positive breast cancer patients. The study met its primary endpoint of total pathological complete response (tpCR) rate, with secondary endpoints showing comparable results between groups.
Through a 2022 license and supply agreement, Organon holds exclusive commercialization rights for HLX11 in the United States, European Union, and Canada, excluding China.
May Health has appointed Colby Holtshouse as President and CEO to lead the company's development of its novel Ovarian Rebalancing™ technology. The technology is a one-time transvaginal ablation procedure designed to restore ovulation in women with Polycystic Ovary Syndrome (PCOS), affecting 10% of women.
The company is currently conducting the REBALANCE study, an IDE clinical trial to support FDA marketing authorization. The procedure uses radio frequency energy to ablate excess androgen-producing ovarian tissue, aiming to establish regular ovulatory menstrual cycles. This in-office treatment is designed for same-day recovery with minimal discomfort.
Holtshouse brings executive experience from Organon, Alydia Health, and Pelvalon. May Health has completed clinical feasibility studies in Europe and the U.S. and is actively enrolling patients for its IDE clinical study in the United States.
Organon (NYSE: OGN) announced positive results from the Phase 3 ADORING 3 study of VTAMA® (tapinarof) cream for atopic dermatitis treatment. The analysis showed that after achieving treatment success, patients maintained low disease activity during an average 80-day treatment-free period.
The 48-week open-label study involved 728 patients, with 378 achieving completely clear skin. Key findings revealed that 84% of patients maintained mild disease (vIGA-AD score of 2) at the end of the treatment-free interval, with a mean weekly PP-NRS score of 2.9 for itch and an EASI score of 3.4.
The most common treatment-emergent adverse events included folliculitis (12.1%), nasopharyngitis (6.9%), and upper respiratory tract infection (6.9%). The study reported low discontinuation rates due to adverse events (2.6%). VTAMA cream received FDA approval in December 2024 for atopic dermatitis treatment in adults and children aged 2 years and older.
Organon (OGN) reported full year 2024 revenue of $6.4 billion, up 2% as-reported and 3% at constant currency. The company achieved diluted earnings per share of $3.33 and non-GAAP Adjusted diluted earnings per share of $4.11. Adjusted EBITDA reached $1.96 billion with a 30.6% margin.
For Q4 2024, revenue was $1.592 billion, flat year-over-year. Women's Health remained stable, while Biosimilars declined 18% due to tender timing and pricing pressure. Established Brands grew 2%, benefiting from Emgality and Vtama contributions.
Looking ahead to 2025, Organon projects revenue between $6.125-$6.325 billion, factoring in an approximate $200 million negative impact from foreign exchange. The company expects an Adjusted EBITDA margin range of 31.0-32.0%. A quarterly dividend of $0.28 per share was declared, payable March 13, 2025.
Organon (NYSE: OGN), a global healthcare company focused on women's health, has announced it will release its fourth quarter and full year 2024 financial results on February 13, 2025, before market open. The company will host a conference call and webcast at 8:30 a.m. EST on the same day.
The company has indicated that it does not expect to record any milestone expense in the fourth quarter of 2024. Organon notes that the results are preliminary and subject to quarterly financial statement closing procedures.
Interested parties can access the live webcast through Organon's investor relations website, with a replay available approximately two hours after the event. Institutional investors and analysts must pre-register to participate in the conference call.
Organon (NYSE: OGN) has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference. CEO Kevin Ali and CFO Matthew Walsh will engage in a fireside chat scheduled for Monday, January 13th, 2025, at 3:45 p.m. PT. The event will be accessible to investors, analysts, media representatives, and the general public through a live audio webcast, which can be accessed via the provided conference link.
Organon (NYSE: OGN) announced FDA approval of VTAMA® (tapinarof) cream, 1% for treating atopic dermatitis in adults and children aged 2 and older. The approval came ahead of the March 2025 target date. In pivotal studies ADORING 1 and 2, up to 46% of patients achieved treatment success at Week 8 versus 18% on vehicle.
The drug demonstrated powerful skin clearance with patients remaining treatment-free for ~80 consecutive days in the 48-week long-term extension study. VTAMA showed rapid itch relief within 24 hours and maintained a favorable safety profile. Common side effects included upper respiratory tract infection (12%) and folliculitis (9%).
